Overviewing Phase 3 NIMBLE Trial Design and Patient Population

Aggregator

02 Nov 2026 0 comments

Ali Habib, MD, a neuromuscular specialist at UCI Health, breaks down the phase 3 NIMBLE trial's patient population, four treatment arms, and primary efficacy endpoint while explaining the rationale for studying complement inhibition in gMG.